Intuitive Surgical Intrinsic Value – Q4 Earnings: What Can We Expect from Intuitive Surgical?
January 31, 2023
Trending News 🌥️
Intuitive Surgical Intrinsic Value – Intuitive Surgical ($NASDAQ:ISRG) is a leading medical technology company that designs, manufactures, and markets robotic-assisted surgical systems in the United States and internationally. With the Q4 earnings report on the horizon, investors are wondering what to expect from Intuitive Surgical. The past few quarters have been an exciting time for Intuitive Surgical. Analysts believe that Intuitive Surgical is well-positioned to benefit from the changing healthcare landscape. The company has been making investments in new products and services that will enable it to capitalize on the growing demand for minimally invasive surgeries.
Additionally, the company has been making strides in expanding its presence in emerging markets, which should help it to strengthen its competitive position and drive further growth in the future. When Intuitive Surgical reports its Q4 earnings, investors will be looking for clues as to how the company is performing in this dynamic environment. Analysts are expecting the company to report solid revenue growth and improved margin performance when it releases its financial results. They are also expecting to see continued progress on the product innovation front, as well as further expansion into emerging markets. Overall, investors have high expectations for Intuitive Surgical’s Q4 earnings report, and they are looking forward to seeing how the company is performing in this rapidly changing healthcare landscape.
Share Price
With INTUITIVE SURGICAL‘s fourth quarter earnings report just around the corner, investors and analysts are eagerly awaiting to find out what the future holds for the company. On Monday, INTUITIVE SURGICAL stock opened at $256.8 and closed at $256.0, down by 0.3% from the previous closing price of $256.8. The stock has been volatile throughout the past year, so investors are keen to understand what the results of the Q4 report will be. Analysts are expecting an increase in sales of INTUITIVE SURGICAL’s robotic surgery systems this quarter as hospitals and healthcare providers continue to invest in the technology.
In addition, analysts anticipate that the company’s increasing focus on developing its services business will boost revenue this quarter. Investors are hoping that INTUITIVE SURGICAL’s Q4 earnings report will provide an indication of the company’s future performance, especially with the anticipated growth in robotic surgery and services sales. With the announcement of its fourth quarter earnings, investors and analysts alike will be able to make more informed decisions about whether to buy or sell shares of INTUITIVE SURGICAL. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Intuitive Surgical. More…
| Total Revenues | Net Income | Net Margin |
| 6.22k | 1.32k | 21.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Intuitive Surgical. More…
| Operations | Investing | Financing |
| 1.62k | -2.46k | 43 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Intuitive Surgical. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 12.97k | 1.86k | 32.59 |
Key Ratios Snapshot
Some of the financial key ratios for Intuitive Surgical are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 11.6% | 4.7% | 25.3% |
| FCF Margin | ROE | ROA |
| 17.3% | 8.6% | 7.6% |
VI Analysis – Intuitive Surgical Intrinsic Value
VI App has simplified the analysis of the company and its intrinsic value. According to VI Line, the intrinsic value of Intuitive Surgical‘s share is around $298.3. Currently, Intuitive Surgical’s stock is being traded at $256.0, a fair price that is undervalued by 14%. Analysts use the VI App to evaluate the company in various aspects such as profitability, financial stability and efficiency. The app also helps to calculate the intrinsic value of the Intuitive Surgical share and compare it to its current market price. Through this comparison, it can be seen that Intuitive Surgical’s current price is undervalued compared to its intrinsic value. Analysts also use the VI App to evaluate the company’s performance in terms of revenues, expenses, and cash flows. The app can provide insight into the company’s performance in various metrics such as operating margin and return on equity. This helps to identify the strengths and weaknesses of Intuitive Surgical’s management team and their ability to deliver profitable results. The VI App also provides information on Intuitive Surgical’s competitive landscape and its competitive advantages. It helps to identify the company’s rivals and their competitive positioning. This helps to understand the company’s competitive advantages and how they can be used to gain an edge in the market. Overall, the VI App has simplified the analysis of Intuitive Surgical and its intrinsic value. Its current price is undervalued compared to its intrinsic value, presenting an opportunity for investors to take advantage of the company’s potential. More…
VI Peers
The company’s da Vinci surgical system consists of a surgeon’s console, a patient-side cart and a vision system. The company’s competitors in the robotic surgery market include Stryker Corp, Medtronic PLC, Becton, Dickinson and Co.
– Stryker Corp ($NYSE:SYK)
With a market capitalization of $84.98 billion as of 2022, Stryker Corporation is one of the world’s leading medical technology companies. Headquartered in Kalamazoo, Michigan, the company offers a broad range of products and services in orthopedics, medical and surgical, and neurotechnology and spine that help improve patient care and quality of life. The company’s products include implants used in hip, knee and shoulder replacements, as well as instrumentation and software used in operating rooms and for patient rehabilitation. In addition, Stryker offers a wide range of products and services for minimally invasive surgery, including robotic-assisted surgery systems. The company’s return on equity was 10.79% as of 2022.
– Medtronic PLC ($NYSE:MDT)
Medtronic PLC is a medical technology company that develops and produces a variety of medical devices and software products. The company has a market capitalization of 112.31 billion as of 2022 and a return on equity of 7.49%. Medtronic PLC’s products are used in a wide range of medical procedures, including cardiovascular, neurological, and orthopedic procedures. The company’s products are sold in over 150 countries around the world.
– Becton, Dickinson and Co ($NYSE:BDX)
Becton, Dickinson and Co is a medical technology company that manufactures and sells medical devices, laboratory equipment, and diagnostic products. The company has a market cap of 64.37B as of 2022 and a return on equity of 6.42%. The company’s products are used in a variety of medical procedures, including blood transfusions, IV start kits, and diabetes care.
Summary
Intuitive Surgical is expected to report strong Q4 earnings, driven by strong demand for its robotic surgery products. With the company’s robotic surgical systems being used in a variety of surgeries, from cardiology to general and urology procedures, analysts expect the company to continue to benefit from increased usage of its products in the coming quarters. Intuitive Surgical is also expected to benefit from the growth of its services revenue, as the company continues to invest in training and services for hospitals and medical centers. The company’s stock price has seen a steady increase over the past year and expectations for Q4 earnings are high.
